GlobeImmune, Inc.
GBIM
Get informed when a big investor buys or sells
+ FollowMarket Cap$575
Close$
Share Statistics
| Market cap | $575.00 |
|---|---|
| Enterprise Value | $-8,693,143.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.48 |
| Beta | -8.93 |
| Outstanding Shares | 5,751,574 |
Return
| Return on Equity | -96.21% |
|---|---|
| Return on Assets | -21.17% |
| Return on Invested Capital | -36.77% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | 0.0 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -1.4 |
| Enterprise Value to EBIT | 4.2 |
| Enterprise Value to Net Income | 4 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About GlobeImmune, Inc.
2 employees
CEO: Donald Bellgrau GlobeImmune, Inc., a biopharmaceutical firm based in Louisville, Colorado, and founded in 1995 (originally Ceres Pharmaceuticals, Inc. until its rebranding in May 2001), specializes in creating therapeutic products for both cancer and in...